NEW YORK (GenomeWeb News) – Leerink Swann today downgraded Fluidigm to Market Perform, saying the company "could take a breather in the near term" after a 30 percent spike in its stock since the start of the year.

In lowering Fluidigm from a previous Outperform rating, analyst Dan Leonard added that he sees "better risk/reward" in Genomic Health and Luminex.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.